Combinatorial Microfluidic Devices for Studying Thrombosis

用于研究血栓形成的组合微流体装置

基本信息

  • 批准号:
    7330168
  • 负责人:
  • 金额:
    $ 4.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2008-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): DESCRIPTION. The goal of the proposed research is to understand how the generation of thrombin at the surface of platelets stabilizes blood clots. The primary roles of thrombin in clot formation are to catalyze fibrin polymerization and activate platelets. Which of these two mechanisms is most responsible for clot stability and under what flow conditions is unknown. The central hypothesis for the proposed research is that at venous shear stresses, stable clots can form in the absence of platelet activation but at arterial shear stress, platelet activation is the predominant mechanism for stabilizing clots. To study clot stability, we will use a novel microfluidic tool to introduce soluble factors into flowing blood. The rationale for this approach is that blood is a moving biological fluid in vivo, and therefore it is important to study blood phenotype in vitro under physiologically relevant flow conditions. The formation and morphology of the resultant clots will be measured by phase contrast, fluorescence, and electron microscopy methods. The stability of clot will be determined by analyzing its fragmentation under high shear stress. This innovative approach is expected to yield the following outcomes. In specific aim 1, we will determine how thrombin flux.affects fibrin polymerization, which is important because it will identify the amount of thrombin generation needed under flow to form a fibrin clot. In specific aim 2, we will decouple fibrin polymerization from platelet activation to determine the relative role of these two mechanisms in forming stable clots. By isolating the mechanism(s) that are responsible for clot stability at different flow conditions we expect to gain further insight into the pathology of bleeding disorders and embolism. LAY SUMMARY. The goal of this research is to understand the mechanisms responsible for forming stable blood clots. Poor clot stability is the result of bleeding disorders like hemophilia and the cause of stroke by emboli shedding from preexisting clots. By unraveling the mechanisms responsible for clot stability, this research will identify new therapeutic targets for individuals who suffer from these diseases.
描述(由申请人提供):描述。拟议研究的目的是了解血小板表面凝血酶的生成如何稳定血凝块。凝血酶在凝块形成中的主要作用是催化纤维蛋白聚合和激活血小板。这两种机制中哪一种对凝块稳定性最负责,以及在何种流动条件下最负责,目前尚不清楚。本研究的中心假设是,在静脉剪切应力下,稳定的血块可以在没有血小板激活的情况下形成,但在动脉剪切应力下,血小板激活是稳定血块的主要机制。为了研究凝块的稳定性,我们将使用一种新型的微流体工具将可溶性因子引入流动的血液中。这种方法的基本原理是血液在体内是一种移动的生物流体,因此在生理相关的流动条件下研究体外血液表型是重要的。所产生的凝块的形成和形态将通过相衬、荧光和电子显微镜方法来测量。通过分析其在高剪切应力作用下的破碎情况,可以确定凝块的稳定性。这一创新方法预计将产生以下结果。在具体目标1中,我们将确定凝血酶通量如何。影响纤维蛋白聚合,这是重要的,因为它将确定所需的凝血酶的量下流动形成纤维蛋白凝块。在具体目标2中,我们将分离纤维蛋白聚合和血小板活化,以确定这两种机制在形成稳定凝块中的相对作用。通过分离不同血流条件下导致凝块稳定性的机制,我们期望进一步了解出血性疾病和栓塞的病理。总结。这项研究的目的是了解形成稳定血凝块的机制。凝块稳定性差是血友病等出血性疾病的结果,也是由先前存在的凝块脱落的栓塞引起中风的原因。通过揭示凝块稳定性的机制,本研究将为患有这些疾病的个体确定新的治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Keith B Neeves其他文献

Keith B Neeves的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Keith B Neeves', 18)}}的其他基金

ESTEEMED Scholars Program in Bioengineering at the University of Colorado Denver
科罗拉多大学丹佛分校生物工程受人尊敬学者计划
  • 批准号:
    10438424
  • 财政年份:
    2022
  • 资助金额:
    $ 4.68万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 4.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 4.68万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 4.68万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了